Compare Northrop Grumman Corporation (NOC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs GeneDx Holdings Corp — how do they compare? Northrop Grumman Corporation trades at $519.79 (market cap $73.24B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: Northrop Grumman Corporation is far larger — about 28.4× GeneDx Holdings Corp's market cap, and Northrop Grumman Corporation pays a 1.92% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| NOC | WGS | |
|---|---|---|
Market Cap | $73.24B | $2.58B |
Sector | Industrials | Technology |
52-Week High | $768.02 | $167.51 |
52-Week Low | $496.02 | $34.51 |
Enterprise Value | $87.23B | $2.61B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $518.58, up 0.7% with a bullish technical oscillator signal despite bearish moving averages. The company shows strong fundamentals with consistent earnings beats, 10.48% net margin, and record $105 billion backlog. Recent news highlights defense spending growth and successful technology tests, while institutional ownership increased significantly in Q2 2026.
Outlook remains positive with 57% analyst buy ratings and $618.43 consensus target offering 19% upside. Key risks include defense budget volatility and execution challenges on large contracts. Revenue growth acceleration to 10.48% margin by 2026 supports valuation at reasonable 16.37 P/E multiple.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
